AI That Pays: Lessons from Revenue Cycle

Talk transcript

1. 0:00

   [on hold music] So great to be here today.

2. 0:16

   Uh, excited to talk to you about a little bit of, uh, the healthcare system that often gets overlooked. It's about a healthcare system that actually continues to grow in multiple dimensions.

3. 0:25

   Over the past couple of decades, its size, cost, and complexity outpace many other benchmarks. That's because right now, forty percent of hospitals operate at a negative margin.

4. 0:36

   Let me put it another way. Almost half the hospitals in the country are losing money. It's b-- Uh, and it's not because of the clinical costs. It's because of the broken and manual processes around the revenue cycle.

5. 0:48

   There's delays, denials, a lot of rework, a lot of the lost revenue.

6. 0:52

   My name is Nathan. I'm the head of AI at Ensemble Health Partners, and we work with hundreds of hospitals and health systems in the US to manage the revenue cycle.

7. 1:01

   We're about fourteen thousand people, a-and we've been a leader on the quality side within the industry.

8. 1:08

   Uh, as an end-to-end solution, that means we support the entire s-- uh, process, every stage, uh, and it gives us a really unique lens into, uh, all the problems and inefficiencies that occur throughout the entire process, and also an opportunity to stop them, uh, before they happen.

9. 1:26

   Revenue cycle management (RCM) refers to the financial process, uh, of the patient's journey, uh, within the healthcare system.

10. 1:35

    And it's traditionally thought of as a series of steps, uh, that go, that goes from one to the next.

11. 1:43

    And just a little bit about how I, I got here. Uh, I started my career in tech, working at Google, building operational-- software for operational teams, and then working, uh, in speech recognition and language modeling.

12. 1:55

    Uh, back in my day, which is now, like, over ten years ago, we were comparing language models that took, you know, traditional models with Google-scale data and compared them to deep learning models, trying to make them compete with each other and see which one worked better.

13. 2:08

    But one of the really interesting projects that we worked on was called, what is now called Ambient. Um, this is one of the things that, um, where people are trying to use this technology to improve the a-administrative burden for, um, for, for, for doctors.

14. 2:25

    Um, that's because oftentimes doctors will spend, you know, hours after they see a patient writing, documenting, and creating notes for themselves. Um, while we weren't successful back, back then, uh, today, there's multiple projects and multiple, uh, uh, multiple groups launching this, uh, and making it commercially viable.

15. 2:45

    And so it's been really successful and really exciting to see that change.

16. 2:54

    Then I spent a little time, uh, in the world of startups, in the world of biotech. Uh, I changed both the scale and the domain that I worked in, and it was very exciting.

17. 3:03

    I was really excited to work on a very, uh, strong mission, a really exciting mission where we had a, a big opportunity to make a big impact. I started first in diagnostics.

18. 3:12

    Uh, this is where I built models, uh, that... and, and built teams to detect cancer from blood. Um, the goal was to give early insight into whether or not a patient had cancer or not.

19. 3:24

    And we used machine learning to look at the blood and look for biomarkers and look across multiple datasets and patients to identify, you know, where might be the signal for cancer.

20. 3:35

    After spending some time there, I, uh, and seeing the company grow from thirty people to over three hundred people, I ended up at an even smaller therapeutic startup. Uh, we worked on novel datasets, looking for unique interactions in complex microbiome communities to try to identify compounds that could be unique and, uh, uh, really valuable in, uh, drug

21. 3:55

    discovery. And that's the thing. When most people think about AI, uh, in healthcare, these are, these are the things that most people think of, right? There's diagnostics, there's imaging, there's other ways to improve, uh, documentation and, uh, decision-making for clinicians and drug discovery.

22. 4:13

    And these are really impactful and really important problems. Uh, you know, I, I, I really enjoyed working on them and-- but they are some of the toughest and hardest to solve.

23. 4:21

    Um, but that's also because some of the benefits are going to be massive as we continue to see groups and organization crack parts of it and make, make headway.

24. 4:29

    Um, we're, we're seeing a lot of change already. But there is another part of the system, the healthcare system, that's not nearly as flashy, not ne-- doesn't nearly have the same attention, you know, on research or in media, um, that, uh, that also has a huge measurable real impact, uh, and is also ripe for, uh, AI disruption.

25. 4:50

    And that's the healthcare-- uh, the financial side of healthcare. Uh, right now, we estimate that twenty percent of the GDP, uh, is, uh, is, is attributed to the healthcare system.

26. 5:01

    A large proportion of that is the administration of healthcare.

27. 5:06

    Uh, this is billing, insurance-related things, um, but it starts from, like, the very beginning through to the very end of the patient's journey, uh, with any healthcare provider, starting with eligibility checks, registration, there's documentation, medical coding, denial management, so on and so forth.

28. 5:25

    Um, oftentimes, these aren't things that you'll see when you visit a pa-- uh, doctor's office, uh, not unless you're, you encounter, like, a really challenging situation or you lack coverage or, um, you face some complication with, with your care.

29. 5:39

    Um, but, uh, this process is very complex because it is very manual, it is very rules-driven, and very inconsistent. Um, and in-- over the past three decades, uh, this healthcare administration in general has-- the p-- number of people working in healthcare administration has increased thirtyfold.

30. 5:56

    Um, and but in the same time period, the number of clinicians, clinicians, excuse me, has barely doubled.

31. 6:02

    And so it just goes to show how much faster, how much more complex, how much, how, how much, how much more quickly this area grows compared to the clinical side of healthcare.

32. 6:12

    And just another note about terminology. I'll, I'll keep using these words: patients, providers, and payers. Patients, I think we all can understand those are the people who receive care.

33. 6:21

    And providers are the ones who deliver it. People like the hospitals, the specialty offices, the specialists, nurses, and doctors that actually conduct and provide care, medical care to the patients.

34. 6:32

    And the payers are, are those who provide the funding. So largely insurance companies, which would be p-private payers, but also other government institutions like Medicare and Medicaid.

35. 6:45

    And just to ma-- Um, and just to help make that more concrete, right? The, the, the cost and complexity of healthcare is really related-- Uh, is really correlated.

36. 6:56

    We, there-- We estimate a large amount of the, the cost associated with healthcare is actually related to friction. And in this case, friction means the inefficiencies around communicating back and forth between payers and providers and patients.

37. 7:09

    And often a lot of that actually results in, um, uh, in, in the same situ-- Same outcome, right? Either the claim gets paid or it doesn't get paid.

38. 7:18

    Uh, one of the things we'll talk about is denials, because that's one of the biggest components of friction. And that's because it's both time and money for the provider to manage, appeal, and work through that process.

39. 7:30

    And then with, again, very slim margins, uh, for these hospital systems, um, any, any, any impact or any change in the appe-- Uh, denial rate can have a huge impact.

40. 7:42

    And ultimately, AI has a big opportunity to shift resources from this bureaucracy, this, this friction, towards hopefully something else, right? Something more productive, we might agree, would be s-- Like, the clinical care or anything else that we've, uh, we've described.

41. 7:59

    So just to make it, uh, concrete for you guys, this is an example of what a claim might look like and f- and, uh, also how much conversation occurs between the patients, uh, well, largely the providers and the payers, you know, before, during, and after a, a patient visit or a patient encounter.

42. 8:17

    In this case, this claim was denied four separate times and appealed and s-- Uh, appealed four separate times as well. Uh, the, the pa-- Uh, the provider had to send, uh, documentation multiple times, uh, through multiple interfaces and probably through multiple different, uh, manual processes.

43. 8:36

    And for the provider, they didn't receive payment for, you know, two hundred days until after the, uh, procedure occurred.

44. 8:44

    Uh, and, and with AI happening, you know, across the field, you know, providers aren't the only one looking to AI to make and improve their process. Payers are also thinking about it as well.

45. 8:57

    They've also increased their denial rates. They're, they're leveraging AI as well for increasing the volume that, um, they're able to adjudicate and to identify, uh, issues for denials, um, making this entire process more, um, more, more strenuous and, uh, and creating a much larger backlog for all these providers.

46. 9:19

    And the thing is that most of these denials aren't necessarily-- Don't necessarily require a better appeal system. It's not like they need a, a smarter appeal system. They just need a way to avoid errors that, uh, cause these in the first place.

47. 9:32

    That is, most of the time, they're not necessarily medical agreements, they're just technical errors in registration or missing data that if we were to put them together in the right way the first time around, we could avoid a lot of this, uh, friction.

48. 9:46

    So how at Ensemble are we hoping to be able to solve this problem? Uh, we think because we are a end-to-end, uh, uh, RCM organization, full service provider, we have an opportunity to see the longitudinal data, connect the dots between-- From the very beginning of the process to the very end of the process, and, and, and really

49. 10:04

    make, uh, make a change before the, uh, error occurs. One of the first situations I'll talk about is, is prior auth. Um, this is, uh, this is an issue that affects the entire industry.

50. 10:18

    And prior auths occur because the provi-- Um, payers have r-required providers to,

51. 10:25

    um, to ask for permission for certain procedures. Um, but it's really challenging because it's often not clear when a prior auth is required. You sometimes have to go to the pay-- The payer portal and say, you know, "Is this procedure-- Um, is this-- Does this procedure require prior authorization?"

52. 10:39

    And even when you do, sometimes they still might deny it because it was incorrect or, uh, uh, it, it just-- The policy had changed.

53. 10:48

    And I think this is where we really think we have an opportunity to change, uh, uh, to, to basically correct the error before it happens, because we can see that data from, you know, see all the historical data from the beginning part where prior auths are requested, um, and, and acquired, um, to the end of the process

54. 11:07

    where we see the final denials. Uh, where AI can help, uh, not only can we try to predict denial, we can also try to identify and correct the, the, the denial.

55. 11:18

    So, um, an example is, like, if we, if we see certain procedures and we know that, uh, often another denial reason is that, uh, the procedure was missing from the original document.

56. 11:28

    And so we can try to flag that early and say, "If you're looking at these procedures, you actually might actually want this other one." And finally, even the actual process of acquiring a, a prior authorization is a big opportunity.

57. 11:39

    There's a b-- It's a manual process. It requires documentation from different parts of the system, um, to be put together by someone and, and sent off to the payers, um, to, to, to make that, uh, request, um, for, for prior authorization.

58. 11:57

    But sometimes we, we are-- [chuckles] We're not as successful. Uh, sometimes it still, it still may be the case that, um, uh, uh, denials may still occur. Um, we can't always avoid denials, um, but o-- We're, we're really But we're excited because GenAI really has an opportunity to help us accelerate, uh, and improve that process as well.

59. 12:18

    Uh, the, this case study I'll talk about right now is, uh, called clinical denials, and this occurs when the payer and the provider disagree about what was medically necessary, um, to, to care for the patient.

60. 12:33

    And w- when, when this happens, uh, the provider has, uh, in order for them to appeal, they have to go through a process where they have to build the, um, build the an- entire appeal packet.

61. 12:43

    Um, they'll need to look through the patient record. They'll look through guidelines or standard guidelines of care to identify what, um, uh, what, what care should have been provided to the patient.

62. 12:56

    They look through payer policies to see what, which would or would not be covered, and this is all a very time-consuming process. Some of these EMRs or electronic medical records are hundreds of pages long.

63. 13:06

    Uh, they have, um, they have all types of data in them, text, images, labs, notes, tables. Uh,

64. 13:15

    uh, the clinical guidelines themselves have, you know, hundreds of clinical guidelines, and for different situations we'll-- you'll need different, different, um, different guidelines. And all this is done under tight deadlines to make sure that you respond in time to the payer after the denial.

65. 13:31

    And all this means that there's a, there's a very real and limiting factor of, you know, how many expert clinicians can we get, um, into the process to help us, um, build and generate these denials-- uh, appeals, excuse me.

66. 13:45

    Uh, you'll [laughs]-- you-- as you might expect, you know, GenAI can actually d-, uh, uh, generate an appeal letter for you. An off-the-shelf one can, if you prompt it, will give you some appeal letter.

67. 13:57

    Um, but unfortunately, that alone wasn't sufficient. We found that when we worked directly with our c- uh, clinical experts that, uh, off-the-shelf models alone wasn't sufficient. And so we really worked hand in hand to develop, uh, um, a model and a pipeline that allows, uh, the-- not only the, the letter to be-- to meet the standard, the

68. 14:16

    quality standard, um, that we have as an organization,

69. 14:20

    uh, but also to allow the clinical expert to make the final decision on whether or not, uh, the letter meets the, meets the standard of quality, uh, before it gets submitted to the, to the payer.

70. 14:34

    And this is important because there, there's also complexity around the clinical appeal process. There's different service lines, different, uh, different clients, and all that, all that gets put together in our GenAI system to make sure that we can deliver these appeals, uh, more quickly and more consistently.

71. 14:52

    We've seen already that we're, uh, increasing the speed of the process, a forty percent reduction in time, uh, sometimes even more. Um, we've also seen higher quality. We've been able to measure quality in terms of the overturn rate.

72. 15:04

    How often are we seeing, uh, uh, appeals being over-- denials being overturned? Uh, and, uh, we've also seen the, the, as a result, the volume grow. But one thing I really want to point out here is that as, as part of this operational and service team, we're able to really measure the, the ROI directly.

73. 15:22

    It's not just, like, a hand-wavy, "This is value." We're tracking it very specifically and measuring it, um, uh, very concretely. And that's one of the really exciting things about, uh, uh, bringing, bringing, uh, bringing AI to this RCM process.

74. 15:39

    So I know AI won't [laughs]-- I won't purpo- I won't purport to say that AI will be able to solve all of the problems overnight. This is an industry that's been reliant on a lot of processes, um, for a long time.

75. 15:51

    You know, as I said, there's lots of rules. They're inconsistent. It's unstructured. Um, you'll see data scattered across a wide range of systems, and this is one of the things that makes it really challenging to, to bring together as a cohesive or, um, uh, and, and unified process.

76. 16:07

    Um, Ensemble has spent, invested a lot, lot of, uh, uh, a lot already in building up a single consistent, uh, infrastructure to be able to do this, and one of the reasons we have been successful has been because of the, the platform that we call EiQ, where we bring together multiple formats, multiple data formats, um, within, within

77. 16:26

    a single platform. Um, but obviously, there's, uh, still great opportunity to, to be able to do that. You'll see that EMRs have many different format types, and it will challenge any, uh, multimodal LLM to, to parse correctly.

78. 16:43

    We're excited because we already see AI deliver value, as you saw with the clinical appeal letter case, um, but also, uh, in the prior authorization case. We're build-- continuing to build agents for all aspects of the revenue cycle process.

79. 16:55

    But we know automation alone isn't gonna be enough. There's complexity in revenue cycle, uh, that, you know, clicking buttons and pushing things, uh, faster, pushing pieces through faster might not be the only way to do it, right?

80. 17:08

    Like, there's really an aspect of reasoning and connectivity that, uh, that we think about when we think about, you know, how to take errors that occur at the end of the process, like the appeal process or the denial process, and try to fix them upstream and early on, early on.

81. 17:22

    And what we're really hoping for and we're, we're really excited about is being able to not just build better tooling, but also a smarter, more coordinated system that allows us to reduce and r-, uh, reduce waste in the overall revenue cycle process.

82. 17:39

    So that's why I'm really excited to be Ensem- at Ensemble. I think we have a unique position to lead this transformation. We have the right data set. We've been building, uh, the, the right team as well to bring all the experts from multiple disciplines to achieve this goal, and we have the full scope of the RCM process

83. 17:56

    to not only collect the data, but also intervene and act on behalf of our clients.

84. 18:01

    I thank you re-- I thank you all so much for your attention. Uh, I hope this gives you a new way to think about AI and healthcare, and if, if you have a chance, please find me and, uh, connect with me afterwards.

85. 18:11

    Thanks so much. [upbeat music]